Related Experiment Video
Updated: Sep 19, 2026
Venous Thrombosis Assay in a Mouse Model of Cancer
Published on: January 5, 2024
Characteristics of Cancer-Associated Thrombosis Based on Changes in Clinically Measurable Coagulation Factors and
Makoto Hiraide1, Chikao Yasuda2, Ryuji Kawaguchi3
1Department of Clinical Assessment, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
Objectives:
This exploratory, cross-sectional study aimed to examine the association between coagulation factor activity and coagulation/fibrinolysis markers and the presence of cancer-associated thrombosis (CAT).
Methods:
Patients diagnosed with cancer complicated by thrombosis and those without thrombosis between November 1, 2020, and December 31, 2022 were included. The clinical characteristics and values of each coagulation factor and coagulation/fibrinolysis marker in the CAT and non-CAT groups were compared.
Results:
Of the 117 patients analyzed, 22 (18.8%) had CAT and 95 (81.2%) did not have CAT. Fibrinogen/fibrin degradation product (FDP), D-dimer, alpha2-plasmin inhibitor-plasmin complex (PIC), fibrin monomer complex (FMC), thrombin-antithrombin complex (TAT), and soluble fibrin (SF) levels were significantly higher in the CAT group than that in the non-CAT group. Receiver operating characteristic curve analysis was performed, and the proportions of patients with CAT were 7.9% when the number of factors with a value higher than the cutoff was 0 among the 6 factors of FDP, D-dimer, PIC, FMC, TAT, and SF levels; 17.1% for factors 1-3 and 31.6% for factors 4-6.
Conclusions:
When hypercoagulability and hyperfibrinolysis coexist in patients with cancer, CAT is likely to be present, and it is necessary to confirm the presence of CAT at an early stage.
